Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
Krystal Biotech, Inc., a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States.
It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis.
The company also develops KB408 for Alpha-1 antitrypsin deficiency; and KB301 for aesthetic skin conditions.
Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 6, 24 | 0.03 Increased by +101.70% | 0.15 Decreased by -80.00% |
| Feb 26, 24 | 0.30 Increased by +124.00% | -0.38 Increased by +178.95% |
| Nov 6, 23 | -0.69 Increased by +41.03% | -0.29 Decreased by -137.93% |
| Aug 7, 23 | -1.25 Decreased by -13.64% | -0.74 Decreased by -68.92% |
| May 8, 23 | -1.76 Decreased by -77.78% | -1.44 Decreased by -22.22% |
| Feb 27, 23 | -1.25 Decreased by -31.58% | -1.32 Increased by +5.30% |
| Nov 7, 22 | -1.17 Decreased by -67.14% | -1.22 Increased by +4.10% |
| Aug 8, 22 | -1.10 Decreased by -48.65% | -1.02 Decreased by -7.84% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 8.56 M Increased by +N/A% | 80.75 M Increased by +370.51% | Increased by +943.75% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -33.21 M Decreased by -18.15% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -45.30 M Increased by +9.34% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -32.05 M Decreased by -46.99% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -29.85 M Decreased by -91.48% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -28.11 M Decreased by -71.78% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -49.97 M Decreased by -215.99% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -21.81 M Decreased by -110.02% | Decreased by N/A% Decreased by N/A% |